• Medtronic disclosed new 24-month exploratory results from the TITAN 2 pivotal trial at the 47th AUGS Annual Scientific Meeting.
• The analysis showed durable reductions in nightly urination episodes, with sleep-related quality of life improving for many patients.
• The update supports the clinical profile of Altaviva, an implantable tibial neuromodulation device cleared in September 2025 for urge urinary incontinence.
• Medtronic also launched the ENDURANCE post-approval study, a five-year, real-world trial tracking 170 implanted patients across up to 30 US centers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.